The Ten-Year Plan: How Sandoz Sees GLP-1s Shaping Up
CEO Richard Saynor Also Talks ADCs, Oligonucleotides And Value Added Medicines
In the final instalment of his three-part interview with Generics Bulletin, Sandoz CEO Richard Saynor talks about opportunities on the horizon, including GLP-1s, ADCs and oligonucleotides – and explains why he has no interest in pursuing value added medicines.
